The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis
Authors:
- 21 September 2022
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 82 (14) , 1469-1480
Abstract
Background Polycystic ovary syndrome (PCOS) is the most common endocrine condition in women, impacting several aspects of a woman's life, including reproductive, mental, cardiovascular, and metabolic health. Antidiabetic drugs may have beneficial effects on the endocrine and metabolic states in women with PCOS. Objective This study aimed to compare the effects of oral antidiabetic drugs on reproductive hormones, metabolic and anthropometric markers, and menstrual frequency, in patients with PCOS using network meta-analysis. Methods PubMed, EMBASE, and CENTRAL were searched for studies published up to May 31, 2021. Randomised clinical trials enrolling participants with PCOS were included, for which sodium-glucose cotransporter 2 (SGLT-2) inhibitors, metformin (Met), dipeptidyl peptidase 4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and thiazolidinediones (TZDs) (alone or in combination) were compared with either each other, placebo, or no treatment. A network meta-analysis using a Bayesian approach was performed. The outcomes included changes in endocrine outcomes, metabolic results, menstrual frequency, and anthropometric findings. All research was conducted according to a protocol registered in the PROSPERO database (CRD42021248314). Results In total, we retrieved 3383 studies, of which 47 articles enrolling 2626 participants were included for the network meta-analysis. In comparison to the control groups, Met (MD − 0.41, 95% CI − 0.73 to − 0.09) was more beneficial in reducing serum total testosterone, and GLP-1RAs+Met (MD − 5.44, 95% CI − 10.06 to − 0.89) reduced free androgen index (FAI) more effectively. Thiazolidinediones (MD 9.33, 95% CI 0.15 to 17.99) had a greater effect on sex hormone-binding globulin (SHBG) than Met. For decreasing androstenedione, Met (MD − 1.87, 95% CI − 2.73 to − 1.01), DPP-4 inhibitors (MD − 2.64, 95% CI − 4.77 to − 0.49), GLP-1RAs (MD − 3.06, 95% CI − 5.53 to − 0.62), and GLP-1RAs+Met (MD − 2.97, 95% CI − 5.85 to − 0.09) were more effective than TZDs. The confidence in evidence was often low or very low. Conclusions In this network meta-analysis, GLP-1 receptor agonists in combination with metformin appear to be preferable for improving hyperandrogenaemia. Metformin and TZDs offer the added benefit of improving fasting blood glucose (FBG) and low-density lipoprotein-cholesterol (LDL-C) when compared to the control groups. Metformin combined with GLP-1 receptor agonists or TZDs could be associated with a beneficial effect on menstrual recovery.Keywords
This publication has 29 references indexed in Scilit:
- Dpp4 Inhibitor Sitagliptin As A Potential Treatment Option In Metformin-Intolerant Obese Women With Polycystic Ovary Syndrome: A Pilot Randomized StudyEndocrine Practice, 2018
- Rayyan—a web and mobile app for systematic reviewsSystematic Reviews, 2016
- Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysisBMJ Open, 2016
- American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1Endocrine Practice, 2015
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and ExplanationsAnnals of Internal Medicine, 2015
- Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studiesResearch Synthesis Methods, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Metforminversusacarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind studyGynecological Endocrinology, 2010
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2008
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertility and Sterility, 2004